Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Restless Legs Syndrome Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Restless Legs Syndrome Overview | 7 | 1 |
| Restless Legs Syndrome Therapeutics under Development by Companies | 8 | 1 |
| Restless Legs Syndrome Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Restless Legs Syndrome Products under Development by Companies | 12 | 1 |
| Restless Legs Syndrome Companies Involved in Therapeutics Development | 13 | 6 |
| Alexza Pharmaceuticals, Inc. | 13 | 1 |
| Galenica Ltd. | 14 | 1 |
| Hisamitsu Pharmaceutical Co., Inc. | 15 | 1 |
| Ligand Pharmaceuticals, Inc. | 16 | 1 |
| Mundipharma International Ltd | 17 | 1 |
| Omeros Corporation | 18 | 1 |
| Restless Legs Syndrome Therapeutics Assessment | 19 | 9 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Combination Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 1 |
| Drug Profiles | 28 | 9 |
| (naloxone hydrochloride + oxycodone hydrochloride) ER Drug Profile | 28 | 2 |
| aplindore fumarate Drug Profile | 30 | 1 |
| AZ-008 Drug Profile | 31 | 1 |
| ferric carboxymaltose Drug Profile | 32 | 2 |
| OMS-527 Drug Profile | 34 | 2 |
| ropinirole hydrochloride Drug Profile | 36 | 1 |
| Restless Legs Syndrome Dormant Projects | 37 | 1 |
| Restless Legs Syndrome Discontinued Products | 38 | 1 |
| Restless Legs Syndrome Product Development Milestones | 39 | 4 |
| Featured News &Press Releases | 39 | 1 |
| May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs | 39 | 1 |
| Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome | 40 | 1 |
| Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome | 41 | 1 |
| Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome | 41 | 1 |
| Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease | 42 | 1 |
| Appendix | 43 | 2 |
| Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Expert Panel Validation | 43 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 44 | 1 |